UBS Asset Management Americas Inc. Purchases 6,565 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

UBS Asset Management Americas Inc. raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% in the 4th quarter, Holdings Channel reports. The firm owned 741,196 shares of the medical equipment provider’s stock after buying an additional 6,565 shares during the period. UBS Asset Management Americas Inc.’s holdings in Zimmer Biomet were worth $114,211,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Public Employees Retirement System of Ohio increased its position in shares of Zimmer Biomet by 3.0% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 81,426 shares of the medical equipment provider’s stock valued at $11,085,000 after buying an additional 2,370 shares in the last quarter. Candriam Luxembourg S.C.A. raised its position in shares of Zimmer Biomet by 8.3% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 11,833 shares of the medical equipment provider’s stock worth $1,823,000 after purchasing an additional 902 shares during the period. First Hawaiian Bank lifted its holdings in shares of Zimmer Biomet by 6.9% during the 4th quarter. First Hawaiian Bank now owns 7,823 shares of the medical equipment provider’s stock valued at $1,205,000 after purchasing an additional 508 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Zimmer Biomet by 24.1% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 623 shares of the medical equipment provider’s stock valued at $263,000 after purchasing an additional 121 shares during the period. Finally, Argent Trust Co increased its stake in Zimmer Biomet by 8.9% during the 4th quarter. Argent Trust Co now owns 3,941 shares of the medical equipment provider’s stock worth $607,000 after purchasing an additional 323 shares in the last quarter. Institutional investors own 87.17% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. Piper Sandler increased their price objective on shares of Zimmer Biomet from $185.00 to $195.00 and gave the stock an “overweight” rating in a research report on Friday, February 5th. Truist Financial increased their target price on shares of Zimmer Biomet from $152.00 to $174.00 in a report on Wednesday, January 6th. Morgan Stanley upped their price objective on Zimmer Biomet from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Monday, February 8th. Deutsche Bank Aktiengesellschaft upped their price objective on Zimmer Biomet from $146.00 to $160.00 and gave the company a “hold” rating in a research note on Monday, February 8th. Finally, The Goldman Sachs Group upgraded Zimmer Biomet from a “buy” rating to a “conviction-buy” rating in a research note on Tuesday, December 15th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $165.65.

Zimmer Biomet stock opened at $162.75 on Thursday. The business has a 50 day moving average of $160.20 and a 200-day moving average of $151.65. The company has a market capitalization of $33.90 billion, a P/E ratio of 1,017.25, a P/E/G ratio of 4.32 and a beta of 1.34. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.68 and a 1 year high of $170.05. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.18 and a quick ratio of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 4th. The medical equipment provider reported $2.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.06 by $0.05. The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.08 billion. Zimmer Biomet had a net margin of 0.52% and a return on equity of 10.07%. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.30 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 4.8 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 30th. Investors of record on Monday, March 29th will be paid a $0.24 dividend. The ex-dividend date is Friday, March 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.59%. Zimmer Biomet’s dividend payout ratio is 12.20%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.

Read More: What is the Dow Jones Industrial Average (DJIA)?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.